Global strategic partnerships in regenerative medicine

被引：6

作者：

French, Anna ^{[1
]}

Suh, Jane Y. ^{[2
]}

Suh, Carol Y. ^{[3
,4
,5
]}

Rubin, Lee ^{[2
,6
]}

Barker, Richard ^{[1
]}

Bure, Kim ^{[7
]}

Reeve, Brock ^{[6
]}

Brindley, David A. ^{[1
,6
,8
,9
]}

机构：

[1] Univ Oxford, Oxford UCL Ctr Adv Sustainable Med Innovat CASMI, Oxford OX3 7LG, England

[2] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA

[3] Yale Univ, Dept Genet, New Haven, CT 06520 USA

[4] Yale Univ, Sch Med, Sect Cardiovasc Med, Dept Internal Med, New Haven, CT 06520 USA

[5] Yale Univ, Stem Cell Ctr, New Haven, CT 06520 USA

[6] Harvard Univ, Stem Cell Inst, Cambridge, MA 02138 USA

[7] Sartorius Stedim, D-37079 Gottingen, Germany

[8] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England

[9] UCL, UCL Sch Pharm, Ctr Behav Med, London WC1N 1AX, England

来源：

TRENDS IN BIOTECHNOLOGY | 2014年 / 32卷 / 09期

关键词：

strategic partnerships; cell therapies; regenerative medicine; stem cells; translation; STEM-CELLS; INNOVATION; THERAPIES; INDUSTRY;

D O I：

10.1016/j.tibtech.2014.05.007

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The approach to research and development in biomedical science is changing. Increasingly, academia and industry seek to collaborate, and share resources and expertise, by establishing partnerships. Here, we explore the co-development partnership landscape in the field of regenerative medicine, focusing on agreements involving one or more private entities. A majority of the largest biopharmaceutical companies have announced strategic partnerships with a specific regenerative medicine focus, signifying the growth and widening appeal of this emerging sector.

引用

页码：436 / 440

页数：5

共 10 条

[1] Outlook for the next 5 years in drug innovation [J].

Berggren, Roy ;

Moller, Martin ;

Moss, Rachel ;

Poda, Pawel ;

Smietana, Katarzyna .

NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (06) :435-436

[2] Patients' Attitudes toward the Donation of Biological Materials for the Derivation of Induced Pluripotent Stem Cells [J].

Dasgupta, Ishan ;

Bollinger, Juli ;

Mathews, Debra J. H. ;

Neumann, Neil M. ;

Rattani, Abbas ;

Sugarman, Jeremy .

CELL STEM CELL, 2014, 14 (01) :9-12

[3] Concise Review: Cell Therapies: The Route to Widespread Adoption [J].

Foley, Lucy ;

Whitaker, Michael .

STEM CELLS TRANSLATIONAL MEDICINE, 2012, 1 (05) :438-447

[4] Commercialization of Regenerative Medicine: Learning from Spin-Outs [J].

French, Anna ;

Buckler, R. Lee ;

Brindley, David A. .

REJUVENATION RESEARCH, 2013, 16 (02) :164-170

[5]

Giebel LB, 2005, NAT BIOTECHNOL, V23, P798, DOI 10.1038/nbt0705-798

[6] Academic-industry partnerships 2012 [J].

Brady Huggett .

Nature Biotechnology, 2013, 31 (5) :383-383

[7]

Mason C, 2011, REGEN MED, V6, P265, DOI [10.2217/RME.11.28, 10.2217/rme.11.28]

[8] Open innovation networks between academia and industry: an imperative for breakthrough therapies [J].

Melese, Teri ;

Lin, Salima M. ;

Chang, Julia L. ;

Cohen, Neal H. .

NATURE MEDICINE, 2009, 15 (05) :502-507

[9] Public Private Partnerships: A Marriage of Necessity [J].

Rao, Mahendra .

CELL STEM CELL, 2013, 12 (02) :149-151

[10] Funding Translational Work in Cell-Based Therapy [J].

Rao, Mahendra S. .

CELL STEM CELL, 2011, 9 (01) :7-10

← 1 →